June 2, 2025 06:45 AM EDTUpdated 08:06 AM
Deals
China
Pharma

Bris­tol My­ers bets $1.5B on BioN­Tech's PD-L1xVEGF from Bio­theus

Kyle LaHucik

Biotech Correspondent

BioN­Tech bought out its Chi­na-based biotech part­ner Bio­theus for $800 mil­lion up­front in No­vem­ber. Now, the Ger­man drug­mak­er is set to re­ceive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Roche's ven­ture arm chief to step down in 2026; As­traZeneca obe­si­ty leader has re­tired

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

Ear­ly-stage in­vestor Syn­cona read­justs pri­or­i­ties due to bleak biotech mar­ket

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times